doi:[removed]j.tibtech[removed]

First Page		Document Content
Date: 2010-04-09 07:50:56 Cross-licensing Patent thicket Patent portfolio Gene patent Essential patent Patent Biological patent Implications of US gene patent invalidation on Australia Patent holding company Patent law Law Patent pool		doi:[removed]j.tibtech[removed] Add to Reading List Source URL: www.epip.eu Download Document from Source Website File Size: 213,79 KB Share Document on Facebook

	POLYETHYLENE GLYCOL CONJUGATES OF INTERFERON-BETA-1b WITH ENHANCED IN VITRO BIOLOGICAL POTENCY - European Patent Office - EPB9 POLYETHYLENE GLYCOL CONJUGATES OF INTERFERON-BETA-1b WITH ENHANCED IN DocID: 1s2aB - View Document
	27 JANUARY 2016 BIOSIMILARS DEVELOPMENT - FROM PRE-CLINIC TO MARKET Several biological products, altogether worth over US$60 billion annual sales, are encountering patent expiry byThis opens up the opportunity for DocID: 1rnQJ - View Document
	US 20070028848A1United States (12) Patent Application Publication (10) Pub. No.: USA1 (43) Pub. Date: DocID: 1qnY0 - View Document
	Information about deposit of biological material The application comprises deposits pursuant to section 8a (1) of the Consolidate Patents Act, or sectionof the Consolidate Utility Models Act. A. Identification o DocID: 1q961 - View Document
	The Impact of TRIPS and the CBD on Coastal Communities∗ Anna Rosa Mart´ınez Prat† N`apols 153, 3er 1a, 08013 Barcelona DocID: 1q3Dz - View Document